Tech Holds the Record, Money Rotates
The Nasdaq 100 notched another high as oil slid on Iran diplomacy, but the typical stock kept falling, and the clearest signals were warnings on stretched quality names like VeriSign and Thermo Fisher.
The Signal
The S&P 500 finished flat, the Dow slipped and the Nasdaq 100 made another new high, extending a run carried by a handful of tech giants. Crude slid again after President Trump signaled openness to meeting Iranian officials at the UN and an Iranian official said Hormuz could reopen within a week if the blockade lifts. The Fed's first hike since 2023 has the two-year yield at its highest in more than two years. Fewer than a third of stocks hold their fifty-day average, and sellers outnumber buyers about three to one among names with a readable flow of money.
The Noise
A record index reads like a healthy market, but the typical stock is down on the month. The more useful signal is timing: most of the early accumulation we track landed on the day of the Fed hike, in utilities and industrial equipment makers, the shape of forced selling meeting a quiet buyer. Warnings cluster in energy, health care and software and hardware, which is rotation rather than a broad top. Jefferies cut Marathon Petroleum and Valero to hold today, in line with the refiner warning from the prior session.
Multi-Signal Confluence
VeriSign, which runs the registry for every .com and .net address, is the cleanest bearish read. Three separate reads agree: price near its high while underlying momentum makes lower peaks, fading buying pressure, and a clear bearish turn today. The business is steady, about 435 million dollars of quarterly revenue with roughly half kept as profit, the stock is up about a quarter this year, and Wedbush raised its target this month. The model's fair value is still above the price, so this is a stretch warning at around 33 times trailing earnings, not a broken company.
Thermo Fisher Scientific, the lab tools and services giant, carries a two-signal bearish read confirmed on the weekly chart, inside a health care group where warnings are clustering. Fundamentals are improving, with second-quarter revenue up about ten percent, a roughly four percent organic growth outlook, and a jump of more than four percent after an upbeat investor conference last week. Earnings in late October are the next test.
Rollins, the Orkin parent, is a revisit because the picture changed: a fresh one-year low on Monday, a two percent bounce today, and three reads now agreeing on a possible turn, weekly included. Revenue grew about eight percent last quarter but missed, earnings missed, and growth guidance was cut; analysts average a hold. Model fair value sits more than twenty percent above the price, but a discount can always get deeper.